


PHARMACEUTICAL 2022

Avalo Therapeutics Inc. Rank 412 of 475







PHARMACEUTICAL 2022

Avalo Therapeutics Inc. Rank 412 of 475



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 198% points.

The company's Economic Capital Ratio, given in the ranking table, is -462%, being 185% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	61,845
Cost of Goods Sold	1,491
Intangible Assets	14,447
Liabilities, Current	19,888
Liabilities, Non-Current	2,298
Other Assets	3,922
Other Compr. Net Income	0
Other Expenses	4,178
Other Liabilities	34,946
Other Net Income	-2,438
Property and Equipment	0
Research and Development	59,835
Revenues	5,398
Selling, General and Administrative Expense	21,832

Output Variable	Value in 1000 USD
Assets	80,214
Liabilities	57,132
Expenses	87,336
Stockholders Equity	23,082
Net Income	-84,376
Comprehensive Net Income	-84,376
Economic Capital Ratio	-462%